* Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery p...
CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Appl...
CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology ...
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. (...
CHENGDU, China, Aug. 10, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...
CHENGDU, China, June 26, 2023 /PRNewswire/ -- HitGen Inc. ("HitGen", SSE: 688222.SH) has recently l...
CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("H...
CHENGDU, China, Dec. 11, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...
CAMBRIDGE, England and COPENHAGEN, Denmark, Sept. 28, 2022 /PRNewswire/ -- Vernalis Research ("Vern...
CHENGDU, China, Sept. 5, 2022 /PRNewswire/ -- Vernalis Research ("Vernalis"), a fully owned subsidi...
CHENGDU, China, Aug. 1, 2022 /PRNewswire/ -- "OpenDEL®3.0 – DRUG DISCOVERY PARTNER" webinar will be...
CHENGDU, China, July 27, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("...
CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STA...
CHENGDU, China, March 17, 2022 /PRNewswire/ -- Shanghai Stock Exchange listed company (688222.SH) H...
CHENGDU, China, Feb. 24, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STA...